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ABSTRACT
Antibody Engineering & Therapeutics, the largest meeting devoted to antibody science and technology
and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016.
Each of 14 sessions will include six presentations by leading industry and academic experts. In this
meeting preview, the session chairs discuss the relevance of their topics to current and future antibody
therapeutics development. Session topics include bispeciﬁcs and designer polyclonal antibodies;
antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy;
antibodies for non-cancer indications; novel antibody display, selection and screening technologies; novel
checkpoint modulators / immuno-oncology; engineering antibodies for T-cell therapy; novel engineering
strategies to enhance antibody functions; and the biological Impact of Fc receptor engagement. The
meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will
review progress toward a neutralizing antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh
School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies;
and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab
for multiple myeloma. In a featured presentation, a representative of the World Health Organization’s INN
expert group will provide a perspective on antibody naming. “Antibodies to watch in 2017” and progress
on The Antibody Society’s 2016 initiatives will be presented during the Society’s special session. In
addition, two pre-conference workshops covering ways to accelerate antibody drugs to the clinic and the










Sunday, December 11, 2016
Pre-conference workshop: The nuts and bolts of antibody
development: Accelerating antibody drugs to the clinic
Moderators: James Larrick, M.D., Ph.D., Managing Director
and Chief Medical Ofﬁcer, Panorama Research Institute and
Velocity Pharmaceutical Development and Mark Alfenito,
Ph.D., President and CEO, EnGen Bio, Inc.
This workshop will present a non-exhaustive sampling of
recently developed technologies and approaches to acceler-
ate development of antibody drugs into the clinic. For
example, close examination of the sequences and physical
properties of antibodies that have reached advanced stages
of development will likely provide useful guidelines for
novel antibody developability. Max Vasquez (Adimab) will
kick off the workshop with his analysis of over 140 antibod-
ies providing deep insight into factors to improve successful
outcomes. Next, Devin Tesar (Genentech) will describe efforts
to engineer molecules with long vitreal half-lives to improve
therapy for age-related macular degeneration. A major out-
come of this work is the ﬁnding that hydrodynamic size is a
key contributor to the rate of vitreal clearance. Isolation of sta-
ble, highly productive cell lines remains a critical step in
development of a large scale manufacturing process. Optimi-
zation of pre-clinical Chinese hamster ovary (CHO) cell line
development will be covered by Bo Yu (Larix Bioscience). Big
Pharma and small biotech are increasingly outsourcing the
late stage development and manufacturing of their biologics.
Success at this expensive step can be ‘make-or-break’ for the
drug candidate, so selection of the most appropriate contract
manufacturing organization (CMO) is critical. Stephen Cha-
mow (Chamow & Associates, Inc.) will discuss the process of
successfully identifying and managing a CMO to help ensure
a successful Phase 1 clinical study.
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Monday, December 12, 2016
Insights from integrating immune repertoire data with
other, complex biological data
Co-chairs: George Georgiou (University of Texas at Austin)
and Jamie Scott (Simon Fraser University)
The term, “immune repertoire”, refers to the collection of
immunoglobulins (Igs), B-cell receptors and T-cell receptors
(TcRs) produced by the B- and T-lymphocytes of the adaptive
immune system. These immune-receptor repertoires are
extremely diverse, and comprise multiple cellular subsets. Ini-
tially, “na€ıve” B-cell and T-cell subsets are generated in the bone
marrow and thymus, respectively, by the recombination of
“germline” V, D and J gene segments, yielding VDJ recombi-
nants that encode the V domain of a complete Ig heavy chain or
TcR beta chain. Following a “productive VDJ rearrangement”,
germline V and J gene segments are then recombined to encode
the V domain of Ig light chains or TcR alpha chains. Three
mechanisms of diversiﬁcation at the joints between V–D, D–J
and V–J gene segments lend further diversity to the antigen-con-
tacting regions of Igs and TcRs: imprecise joining, and the addi-
tion of N and P nucleotides. Thus, the diversity of the initial,
“na€ıve” repertoires is produced both by combinatorial diversity
at the levels of germline gene recombination and through the
combination of heavy and light or alpha and beta chains. After
undergoing positive and negative selection, functional na€ıve B-
and T-cell repertoires circulate through the secondary lymphoid
tissues, where they encounter antigens. With the proper stimula-
tion, antigen-binding clones are activated to divide and differen-
tiate into antibody-secreting plasma cells, “memory” B cells, and
activated CD4C and CD8C T cells. In addition, often with the
help of CD4C T cells, B cells undergo isotype switching (from
IgM and IgD to IgG, IgA and/or IgE), and accumulate somatic
hypermutations in their functional IGHV and IGLV gene
regions. Thus, through the process of antigen recognition, anti-
gen-activated B and T cells become “clonally expanded”, and
from successive rounds of somatic hypermutation, B cells will
also form “lineages” expressing clonally related Igs.
B and T cells form the heart of adaptive immune responses,
and are key to our understanding of health and disease, and to
the development of therapeutics and vaccines. As such, there is
keen interest in methods that can characterize the repertoires
of various na€ıve, memory and effector B- and T-cell subsets.
Over the past 5-6 years, high-throughput sequencing (HTS)
has been adapted to characterize antibody and T-cell receptor
repertoires from the blood and other tissues of people and ani-
mals. Brieﬂy, mRNA from B or T cells is converted to cDNA,
their recombined V(D)J regions are then PCR ampliﬁed and
sequenced, using either primers speciﬁc for the entire set of
germline genes or by 50 RACE to cover the 50 end of the V
region, and constant-region-speciﬁc primers to cover the 30end;
this produces tens- to hundreds-of-thousands of sequences. B-
and T-cell clonal expansions can be deduced from analysis of
these sequences, and B-cell clonal lineages can be deduced
from the somatic mutation patterns of closely related clones.
Analysis of B- and T-cell repertoires derived from different cel-
lular compartments (e.g., blood vs. solid tissue) can reﬂect
clonal migration, whereas repertoire analysis of different cellu-
lar subsets can reﬂect pathways of clonal differentiation.
Yet, in view of the amazing insights that immune repertoire
analyses can now provide, there are signiﬁcant bioinformatics
challenges in taking such analyses to the next level of biological
integration. This session is focused on the challenges posed in
integrating immune repertoire data with other, large-scale and
complex biological data. Session co-chair, George Georgiou, will
describe his approach to quantifying individual antibodies com-
prising the serum antibody response through a combination of
HTS of the recombined Ig genes from antigen-speciﬁc B cells and
mass-spectrometric analysis of peptide fragments generated from
antigen-speciﬁc Igs from the blood. Examples of deep analyses of
serum antibodies elicited by vaccination and against pathogenic
cells will be described. Brandon DeKosky (Vaccine Research Cen-
ter, NIH) will follow with the use of paired VH-VL read technol-
ogy in developing sequential vaccines that reiterate the ontogeny
of neutralizing antibody development for a class of HIV-speciﬁc
antibodies. Daniel Emerling (Atreca, Inc.) will report on clinical-
level studies of immune repertoires based on sequence analysis of
the two chains of antibodies. One example involves patients dur-
ing a vaccine trial, with Ig-repertoire analyses of B-cells and plas-
mablasts informing vaccine strategies. Ludvig Sollid (University
of Oslo) has been working on the role of B- and T-cells and anti-
gens in celiac disease; he will describe the interaction of antibody
and TcR repertoires, along with the role of proteolytic products of
the autoantigen, gluten, in driving this disease. Jake Glanville
(Stanford University) has developed methods for deducing anti-
gen speciﬁc B and T-cell receptors out of high-throughput
sequencing data. This would provide a computational approach to
identifying both B- and T-cell clones involved in immunological
processes, including in the absences of knowledge of the etiological
agent. Johanna Olweus (Oslo University Hospital) will describe
her approach of using the TcR-repertoire data derived from
healthy individuals to discover TcRs that can recognize cancer
neoantigens. This provides a way of discovering cancer-speciﬁc
TcRs that can be “implanted” into autologous T cells, then
expanded and activated to speciﬁcally attack a patient’s tumor
cells. These presentations will provide excellent examples of the
burgeoning systems-biology approaches currently under develop-
ment, in which “big data” characterizing different, complex bio-
logical processes are integrated to reveal important new insights
and discoveries.
Power combos: Bispeciﬁcs & designer polyclonal
antibodies
Chairmen: Dennis R. Burton, Professor & Chairman, Depart-
ment of Immunology and Microbial Science, The Scripps
Research Institute, La Jolla, CA, and Paul W.H.I. Parren, Senior
Vice President & Scientiﬁc Director, Genmab, Utrecht, the
Netherlands and Professor Department of Immunohematology
and Blood Transfusion, Leiden University Medical Center, Lei-
den, the Netherlands
Antibodies have naturally evolved to work together. Protec-
tive polyclonal antibody responses against pathogens typically
consist of complex mixtures of antibodies directed against dis-
tinct disease-related targets and epitopes. Antibody mixtures
thereby provide an ability to target disease heterogeneity and
plasticity and to prevent escape. Strikingly, most approved pas-
sive immunotherapy approaches (i.e., based on administering
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puriﬁed, recombinant antibodies with deﬁned speciﬁcity) are
still being developed as monotherapies. In the search for more
potent and effective treatments, it therefore makes a lot of sense
to investigate the educated assembly of antibody combinations
in bispeciﬁc and designer polyclonal preparations. In addition
to widening target binding, antibody-mediated effector func-
tions are more effective when antibodies work in close concert
with each other. This session will report new insights into the
selection and design of bi- and multi-speciﬁc antibody thera-
peutics and investigate the implications for the mechanisms of
action of such products.
The session will start with Davide Corti (Humabs Biomed)
who will discuss the knowledge-based selection of both anti-
body speciﬁcities and therapeutic formats for the development
of optimal combinations of anti-bacterial and anti-viral anti-
bodies for therapy in infectious disease. Gary Kobinger (Uni-
versite Laval) will discuss novel experimental antibody
therapies and vaccines for the treatment of Ebola virus infec-
tion and insights obtained from their emergency compassionate
use. Jin-an-Jiao (SAb Biotherapeutics) will detail the develop-
ment of trans-chromosomal cows with an ability to rapidly
produce human polyclonal antibodies for the treatment of
emergent infectious diseases such as those resulting from infec-
tion with Zika virus and MERS-CoV. After the break, Guanbo
Wang (Nanjing Normal University) will dive into the molecu-
lar mechanism by which IgG antibodies connect to activate
complement, thereby providing insights into how antibodies
might be further improved for enhanced cooperation and effec-
tor activity. Jeffrey Kearns (Merrimack Pharmaceuticals) will
demonstrate how computational model-guided selection led to
the design and development of a polyclonal preparation con-
sisting of three anti-epidermal growth factor receptor (EGFR)
antibodies that surpasses its individual components both in
terms of activity and mechanisms. Joost Neijssen (Genmab)
ﬁnally will discuss the intricacies of selecting optimal anti-
EGFR and anti-cMet antibody binding arms for a bispeciﬁc
antibody. The activity of the bispeciﬁc antibody (Duobody)
against heterogeneous tumors containing EGFR mutations
and/or the cMet pathway in preclinical models will be
addressed.
The informed selection of antibody combos for the design of
bispeciﬁc and polyclonal antibodies represents a strong growth
area in the therapeutic antibody ﬁeld with enormous potential
for the development of antibody therapeutics with increased
potency and breadth.
Tuesday, December 13, 2016, morning
Engineering and application of therapeutic antibodies for
neurodegenerative diseases
Session Co-Chairs: Cynthia A. Lemere, Ann Romney Center
for Neurologic Diseases, Brigham and Woman’s Hospital and
Harvard Medical School; Anne Messer, Neural Stem Cell Insti-
tute, Regenerative Research Foundation; James S. Huston, Hus-
ton BioConsulting, LLC.
As research has increasingly focused on ﬁnding treatments
for neurodegenerative diseases, it has become clear that their
common involvement of misfolded protein aggregation and
accumulation has given way to signiﬁcant differentiation in the
molecular properties of their aggregated proteins. This session
highlights how this has led creative scientists to exploit the
diversity of antibodies to target the proteins underlying neuro-
degenerative disease pathology, with antibodies as detoxifying
species and the vehicles of vaccine action.
Anne Messer (The University at Albany and Regenerative
Research Foundation) will describe her lab’s success at intracel-
lular proteosomal targeting of intrabodies and bound cargo.1,2
This promotes the active degradation of the aggregating pro-
teins in Huntington’s disease (HD) and Parkinson’s disease
(PD), with dramatic clearance of their intracellular aggregates
in disease models. Her investigations of C4 scFv intrabody ther-
apy of neurological disease were the ﬁrst to be conducted with
intrabodies as a treatment for neurological disease, using cellu-
lar,3 Drosophila4 and R65 mouse models of Huntington disease
(HD). This pioneering work was then extended to the PD tar-
get, alpha-synuclein, with emphasis on the challenging NAC
region as a target. In situ and in vivo studies for both diseases
have shown promising therapeutic candidates.
Mike Sierks (Arizona State University) will discuss his
recent experiments on the treatment of PD by scFv targeting of
a-synuclein (a-syn) oligomers delivered using a fusion protein
to pass into target cells.6 Prof. Sierks is a chemical and antibody
engineer with a long commitment to developing treatments for
HD, PD and Alzheimer’s disease. His group was the ﬁrst to
select scFv antibodies that target distinct conformers of PD
neurodegeneration proteins using phage library selection with
atomic force microscopy.7,8 These reagents show potential as
both therapeutics and biomarkers.9-11
Eliezer Masliah (UC San Diego) will discuss his research on
therapeutic antibody12 and vaccine13 approaches for PD, PD
dementia, dementia with Lewy body atrophy, and multiple sys-
tem atrophy. These are related neurodegenerative diseases that
are caused by abnormal accumulation of a-syn aggregates in
brain, which are the second most common cause of neurode-
generation after AD in the elderly. He and his collaborators
recently developed a transgenic mouse neuronal model for PD
that recapitulates the induction of human a-syn ﬁbril forma-
tion.14 Other recent research has been devoted to non-invasive
live cell imaging of a-syn-GFP aggregates in the retina of mice
that are genetically modiﬁed to express this a-syn-GFP fusion
protein, and demonstrate single-chain antibody reduction of
a-syn-GFP accumulation in vivo.15
In AD, clinical trials that exploited active and passive vacci-
nation have focused on full-length amyloid-b (Ab) 1-40 and
Ab1-42, but early results were not sufﬁciently positive to justify
product development, although some early-stage trials are con-
tinuing. Charles G. Glabe (UC Irvine) will discuss his investi-
gations of the structural differences between different forms of
Ab protein aggregates.16 Understanding these species is shown
to be essential, so that precise forms of soluble and insoluble
Ab can be effectively targeted with speciﬁc antibodies during
the progression of AD and offer important opportunities for
AD therapy.17
Cynthia A. Lemere (Brigham and Women’s Hospital and
Harvard Medical School) will describe her research on a candi-
date target in the Ab plaque, pyroglutamate-3 Ab (pyroGlu3
Ab), which now appears to be a major contributor to plaque
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formation and aggregate toxicity. PyroGlu3 Ab is formed by N-
terminal truncation of the ﬁrst two amino acids of Ab followed
by cyclization of Glu-3 by glutaminyl cyclase, resulting in a
hydrophobic and degradation-resistant, pathogenic form of
amyloid.18 The Lemere group was one of the earliest to explore
the use of pGlu-3 Ab as an immunotherapeutic target. She will
present evidence from their recent investigations that reinforce
the potential that passive immunization against pGlu-3 Ab
may offer important avenues for AD prevention and therapy.
She and her colleagues at Harvard Medical School have recently
described striking results that implicate microglia and comple-
ment in early synapse loss in aging and AD.19,20
Tim West (C2N Diagnostics) will discuss the development
of their humanized antibody, 8E12, that recognizes an aggre-
gated, extracellular form of tau thought to be responsible for
pathogenic tau “seeding” between nerve cells in neurodegenera-
tive diseases, including progressive supranuclear palsy (PSP)
and AD. Tau is an intracellular microtubule-associated protein
that, when phosphorylated, forms aggregates that appear to
spread from neuron to neuron and eventually result in the for-
mation of neuroﬁbrillary tangles within the brain. Immuno-
therapy with 8E12 does not require uptake of the antibody by
neurons, and therefore, represents a novel and potentially criti-
cal approach in the suppression of tau pathology in tauopa-
thies. The C2N anti-tau antibody 8E12 program is now being
supported by AbbVie and trials are underway for the treatment
of PSP.
The interface between passive and active immunotherapy
Chairman: Mark Alfenito, Ph.D., President and CEO, EnGen
Bio, Inc.
Vaccines (active) and antibodies (passive) have traditionally
been looked at as agents for prophylaxis and for therapy,
respectively. We are learning that it is increasingly difﬁcult to
keep traditionally separate ﬁelds (e.g., oncology, inﬂammation,
immunology) as cleanly parsed as they once were thought to
be. As our understanding of how processes integrate within a
cell and on a whole-organism basis, we are learning that the
ﬁelds are ever more intersecting and overlapping. So it is with
antibody immunotherapy and vaccinology. This year, for the
ﬁrst time in this conference’s 27-year history, we are introduc-
ing talks and sessions on vaccinology. To that end, this session
is predominantly devoted to disease scenarios where there is a
preexisting therapeutic antibody, and for which there is now a
vaccine in development that is directed to the same target.
What are the advantages of a vaccine over the antibody? This
will be discussed on a case-by-case basis.
One such example is proprotein convertase subtilisin/kexin
type 9 (PCSK9), which is the target for several anti-hypercho-
lesterolemia monoclonal antibodies in late-stage clinical devel-
opment. Bryce Chackerian (University of New Mexico School
of Medicine) will talk about the potential clinical and ﬁnancial
advantages of developing PCSK9 as a vaccine target for the
same indication. Similarly, Yanelys Morera (Center for Genetic
Engineering & Biotechnology, Cuba) will discuss the develop-
ment of the established monoclonal antibody cancer target, vas-
cular endothelial growth factor (VEGF) as a vaccine. Kai Xu
(University of Maryland School of Medicine) will discuss
development of vaccines for the treatment and prevention of
heart failure.
A novel example of combining active/passive immunother-
apy strategies involves the development of a respiratory syncy-
tial virus (RSV) vaccine. Administration of an RSV vaccine in
infants is unsuccessful due to their immature immune system.
Hence, antibody therapy/prevention has been the only treat-
ment route. Gregory Glenn (Novavax) will discuss the devel-
opment of an RSV vaccine for use in new mothers, to pass
along passive immunotherapy to their nursing babies. While
not yet approved, there are several antibodies being developed
to treat the Zika virus. Harry Kleanthous (Sanoﬁ Pasteur) will
discuss efforts to develop a Zika virus vaccine. Finally,Matthew
Macauley (The Scripps Research Institute) will discuss the
opposite end of vaccination: ‘tolerization’. They have developed
a novel CD22 glycan ligand::antigen::nanoparticle platform for
tolerizing the immune system in an effort to mitigate immune
recognition of therapeutic proteins.
Tuesday, December 13, 2016, afternoon
Antibodies for non-cancer indications
Chairwoman: Trudi Veldman, Ph.D., Senior Director Biologics,
Abbvie
This session starts with a continuation of the morning ses-
sion on ‘Antibodies for Neurodegenerative Diseases’ with a pre-
sentation by Lili Huang (Abbvie) on a novel target for multiple
sclerosis. She will share data showing that Repulsive Guidance
Molecule A (RGMa) exhibits potent inhibition on axon regen-
eration and remyelination that can be inhibited with a neutral-
izing antibody to RGMa. Early clinical development in healthy
volunteers and multiple sclerosis patients is currently under-
way. A major challenge for biologics that speciﬁcally target neu-
rodegenerative diseases is the requirement to cross the blood
brain barrier in order to gain effective entry into the central
nervous system to engage the target. Uli Brinkmann (Roche)
will describe speciﬁc antibodies for targeted delivery to, into
and across cells and tissues including new trans-blood-brain-
barrier delivery approaches with release functionality.
The next two talks will cover different approaches for poten-
tial treatment of other types of degenerative diseases such as
Huntington’s disease and ischemic heart disease. Oskar
Smrzka (AFFiRiS AG) will discuss a hypothesis that the intra-
cellular mutant Huntingtin protein (HTT) presents a putative
extracellular compartment that can be targeted with antibodies.
Data will be presented showing that certain protein domains
were successfully targeted and provided mutant HTT lowering
in plasma and organs combined with phenotypic beneﬁt. Ke
Cheng (UNC-Chapel Hill) set out to speciﬁcally target circulat-
ing stem cells to engage with injured cardiomyocytes or endo-
thelial cells in ischemic tissue using bispeciﬁc antibodies. The
targeted stem cells also co-locate with platelets and macro-
phages that naturally target the injury site to create regenerative
cell co-aggregates.
The ﬁnal two presentations cover applications of antibodies
and nanobodies in managing hemostasis and inﬂammation.
Thomas Mikita (Pﬁzer) will describe the generation of high
afﬁnity Factor XIa-speciﬁc IgGs as potential treatment for
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thrombotic disease. To address potential safety concerns, a
potent reversal agent antibody has been created as well. Frie-
drich Koch-Nolte (University Medical Center, Hamburg, Ger-
many) will present the generation and characterization of
nanobodies that block gating of the P2£7 ion channel and
ameliorate experimental glomerulonephritis and contact der-
matitis in animal models.
Novel checkpoint modulators; Immuno-oncology
Chairman: James Larrick, M.D., Ph.D., Managing Director and
Chief Medical Ofﬁcer, Panorama Research Institute and Veloc-
ity Pharmaceutical Development
The management of cancer has dramatically changed over
the past decade with the introduction of novel immunothera-
pies, chief among them inhibitors of checkpoint receptors —
molecules whose function is to restrain the host immune
response. Antibodies inhibiting CTLA4 and PD1-PD-L1 have
shown remarkable clinical beneﬁt. The ﬁeld is evolving rapidly,
with many clinical trials testing novel checkpoint inhibitors
(e.g., anti-LAG3, anti-TIM3), alone, in combination, or with
other targeted therapies. A sampling of novel approaches will
be covered in this symposium.
T cell co-potentiation is new concept recently applied to
enhance immune responses against tumor-associated antigens
(TAA) that synergizes with checkpoint blockade or adoptive-
transfer immunotherapies in mice. Diana Gil Pages (Mayo
Clinic) will introduce this concept with data demonstrating
that anti-CD3 Mono-Fabs strengthen anti-melanoma immune
responses in humanized mouse models in vivo.
Next, Robert Mabry (Jounce Therapeutics) will describe prog-
ress with JTX-2011, an agonist antibody targeting ICOS, (Inducible
T-cell COStimulator, CD278, a CD28-superfamily co-stimulatory
molecule that is expressed on activated T cells). Published studies
indicate that agonistic stimulus of the ICOS pathway during anti-
CTLA-4 therapy results in an increase in efﬁcacy that is about four
to ﬁve times as large as that of control treatments.Xingxing Zhang
(Albert Einstein College of Medicine) will then provide an update
on new members of the T cell co-stimulatory/co-inhibitory B7
family andCD28 family, including B7x, HHLA2 andTMIGD2 dis-
covered in his laboratory.
The PD1 pathway blocks the anti-tumor activity of previ-
ously activated tumor-reactive T cells. However, many patients
do not respond to antibody therapy, possibly because their T
cells were not initially activated. To overcome this deﬁciency,
Suzanne Ostrand-Rosenberg, (University of Maryland Balti-
more County) has developed a novel recombinant protein that
disrupts the PD1 pathway while simultaneously activating
tumor-reactive T cells. Details of this CD80-Fc fusion protein
will be presented.
CD47, a ubiquitous immune checkpoint receptor, is over-
expressed in cancer and drives immune evasion. In order to bypass
tolerability and antigen sink problems arising from CD47 expres-
sion in normal tissue, Novimmune generated dual targeting bispe-
ciﬁc antibodies (biAbs) allowing selective blockade of CD47 on
malignant cells expressing CD19 or mesothelin.KrzysztofMaster-
nak (Novimmune) will describe work with the anti-CD47/CD19
biAb NI-1701 that enhances the phagocytic activity of tumor mac-
rophages and limits myeloid-derived suppressor cell inﬁltration in
vitro and initial human trial translation studies (e.g., non-human
primate safety studies).
Substantial reduction of CD73 enzymatic activity has the
potential to reduce immunosuppressive adenosine levels within
tumors. An anti-human CD73 antibody that suppresses CD73
by two mechanisms: 1) direct inhibition of enzymatic activity
upon binding to CD73; and 2) rapid, near-complete internali-
zation will be described by Bryan Barnhart (Bristol-Myers
Squibb). The IgG2 sequence of this antibody drives superior
internalization of CD73 and enhances CD73 inhibition.
We anticipate that antibody technology will continue to
drive innovative approaches in immuno-oncology. These excit-
ing presentations represent only a limited sampling of the enor-
mous work being carried out on novel checkpoint modulators.
Wednesday, December 14, 2016, morning
Novel antibody display, selection and screening
technologies
Chairman: Andrew Bradbury, Research Scientist and Group
Leader, Los Alamos National Laboratory
The two dominant display platforms (yeast and phage) were
described almost twenty and thirty years ago, respectively, with
both approaches now being used by numerous investigators to
generate antibodies of clinical and research utility. In this ses-
sion improvements in screening and selection approaches will
be covered, as well as improved antibody scaffolds suitable for
speciﬁc therapeutic targets.
Andrew Bradbury (Los Alamos National Laboratory) will dis-
cuss the inherent problems of accessing the diversity present in dis-
play libraries. Theoretical and practical considerations would
suggest that functional libraries should provide speciﬁc binders at
the rate of approximately one binder per ten million clones. How-
ever, as libraries have grown exponentially larger, the number of
isolated/identiﬁed binders has not increased correspondingly. By
comparing the diversity of binders obtained from the same original
na€ıve antibody genetic material screened by: 1) phage display; 2)
phage combined with yeast display; and 3) phage/yeast display
with next-generation sequencing, this talk will illustrate how the
diversity of isolated binders depends upon the screening/selection
methods used. An alternative approach to traditional display tech-
nologies is the use of two hybridmethods, such as yeast two hybrid.
Antonino Cattaneo (Scuola Normale Superiore) will describe the
further development of this technology to select antibodies recog-
nizing speciﬁc targets, particularly how it can be applied to the
selection of antibodies against speciﬁc post-translational modiﬁca-
tions (PTMs). This involves the anchored in vivo site-speciﬁcmod-
iﬁcation of a speciﬁc target, followed by the in vivo (yeast) selection
of antibodies recognizing that modiﬁcation. The selection of func-
tional antibodies against acetylated and conformational targets will
be described. One important advantage of this technique is that
selected antibodies are functional within the cytoplasm. As a result,
in addition to being able to inhibit PTMactivity, selected antibodies
tend to be particularly stable.
The B cell is the perfect display platform, providing both
ampliﬁcation and simultaneous afﬁnity maturation upon
immunization. However, it can be challenging to access the nat-
urally paired genes underlying B cell responses to target. While
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rodents yield hybridomas relatively easily, this is not the case
for humans. Daniel Lightwood (UCB Celltech) will describe
approaches to isolate the memory B, and plasma, cell reper-
toires, involving high-throughput automated B cell culture, and
novel ﬂuorescence-based proximity secretion assay. More
recently these have been developed within the context of drop-
let microﬂuidics. These approaches have been applied to both
immunized animals and humans.
All the approaches described above isolate antibodies on the
basis of their binding properties. However, it is well known that not
all antibodies binding a target have similar activities. Hence the
desire to screen antibodies on the basis of their activities or pheno-
types, rather than merely binding. When such screening is carried
out blind, i.e. without knowledge of the targets recognized, “new”
targets/epitopes may be isolated.Mikael Mattsson (BioInvent) will
illustrate this with a case study in which a function-led discovery
platform was used to identify targets and antibodies with improved
activity compared to standard chronic lymphatic leukemia care.
The platform includes methods for differential cell-based panning
with primary cells, high-throughput functional screening and tar-
get deconvolution. Amultifunctional antibody (BI-1206) identiﬁed
using this platform recognizes FcgRIIB, possesses intrinsic cyto-
toxic activity and blocks internalization of rituximab, as well as
boosting immune effector cell function.
Moving away from biological display platforms, Jennifer
Cochran (Stanford University) will describe a novel microca-
pillary screening approach that can then be interrogated using
a number of different methods. Rather than the traditional phe-
notype/genotype linkage mediated by direct linkage between
protein and encoding DNA, this platform isolates individual
cells in minute capillaries. In addition to being applicable to
protein targets displayed on cell surfaces, this approach can
also be used for proteins that are secreted and not physically
linked to the cells producing them. Furthermore, the platform
can be applied to enzymatic, as well as binding, activities.
Finally, John McCafferty (IONTAS) will describe the crea-
tion of new antibody forms able to recognize inherently difﬁ-
cult targets. These are based on small biologically active
cysteine-rich peptides that have been identiﬁed in a variety of
plants and toxins. By inserting such cysteine-rich peptides into
an antibody complementarity-determining region, the function
of the peptide can be conferred upon the antibody, while simul-
taneously improving half-life and manufacturability. X-ray
crystallography and biochemical assays conﬁrm that both pep-
tide and antibody are correctly folded and active. This approach
has been used to generate antibodies able to block ion channels,
targets that are traditionally difﬁcult to inhibit with traditional
antibody selection methods.
Engineering antibodies for T cell therapy
Chairwomen: Kerry Chester, Professor of Molecular Medicine,
UCL Cancer Institute, University College London, United
Kingdom, and Janine Schuurman, Vice President Research,
Genmab, Utrecht, The Netherlands
Exploiting the exquisite speciﬁcity of antibodies for the redirec-
tion of (polyclonal) T cells for (tumor) cell killing is the theme of
the two sessions on “Engineering Antibodies for T cell Therapy.”
The sessions will explore innovative approaches in this exciting
antibody engineering ﬁeld, from fundamental explorations to
clinical stage. The morning talks will address the latest develop-
ments with the chimeric antigen receptor (CAR) approach, where
T cells are typically redirected by ex vivo engineering to express
an antibody binding domain fused to an activation moiety. The
afternoon session will be centered on bispeciﬁc antibody
approaches redirecting T cells to engage them in target cell killing.
The sessions are designed to be complementary and to generate
lively discussions that will stimulate new lines of thinking.
Engineering antibodies for T cell therapy: CAR-T
and beyond
In the ﬁrst talk of the morning session, Hinrich Abken (Uni-
versity of Cologne) will address the challenge of focusing the
killing activity of CAR-T towards malignant target cells.
Encouraging data will be presented with a CD30 speciﬁc CAR-
T that effectively eliminates CD30C lymphoma cells, but does
not attack CD30 positive hematopoietic stems or progenitor
cells. Next,Wayne Marasco (Dana-Farber Cancer Institute and
Harvard Medical School) will present exciting results with anti-
body-secreting CAR-T cells that manipulate the tumor micro-
environment to increase tumor cell killing efﬁcacy. This
ground-breaking approach could address some of the chal-
lenges of solid tumor targeting by CAR-T cells. Dimiter Dimi-
trov (National Institutes of Health) will then explore the many
antibody engineering questions surrounding the CAR format.
The interrelationships between epitope location, antibody afﬁn-
ity/avidity and efﬁcacy will be brought into perspective and into
relation to several antibody formats, including CAR-T.
After a networking refreshment break, Levi Rupp, (Cell Design
Labs, Inc) will open up the world of intracellular CAR-T engineer-
ing using synthetic Notch (synNotch), which is a novel class of
engineered receptors with potential to drive a speciﬁed program in
the cell, for instance to enable precise recognition of tumor cells.
The exciting utility of synNotch receptors to sense diverse environ-
mental antigens and drive localized, rationally designed response
programs in T lymphocytes will be illustrated. Next, Kate Mac-
Donald (The Centre for Drug Research and Development) will
explore a now role for CAR-T cells in treatment of graft-versus-
host disease (GVHD). Data will be presented on allo-antigen CAR-
Tregs, including a comparison of CAR-Tregs v. polyclonal Tregs in
in vitro and in vivo efﬁcacy of GVHD prevention. In the ﬁnal talk,
David Gilham (Celyad S.A.) will introduce the topic of exploiting
natural killer cell receptors for the development of CAR
approaches. NK-CAR-T cells facilitate the interaction with multi-
ple tumor antigens, potentially reducing the likelihood of antigen-
negative tumor escape variants. Furthermore, pre-clinical models
with this innovative and exiting new approach suggest that pre-
conditioning is not required for therapeutic efﬁcacy.
Wednesday, December 14, 2016, afternoon
Engineering antibodies for T-cell therapy: Bispeciﬁc T-cell
recruitment and more developments with engineered
T cells
Chairwomen: Janine Schuurman, Vice President Research,
Genmab, Utrecht, The Netherlands and Kerry Chester,
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Professor of Molecular Medicine, UCL Cancer Institute, Uni-
versity College London, United Kingdom
The afternoon session opens with a comparison of the two
major topics covered in this daylong session on engineering
antibodies for T-cell therapies. Bent Jakobsen (Immunocore
Ltd and AdaptImmune Ltd) will show the applicability of T-
cell receptors (TCRs) as binding domains for both CD3-
directed bispeciﬁc and adoptive T cell therapies. He will com-
pare and discuss both therapeutic approaches, focusing on the
differences of both approaches with regards to optimization of
TCRs and the biological effects. Blinatumomab, a fragment-
based bispeciﬁc CD19xCD3 antibody, validated the power of
CD3 bispeciﬁcs: engaging T cells in B cell malignant cell killing.
However, a fragment-based approach leads to short half-life
and a need for frequent dosing. Recent progress in the ﬁeld of
bispeciﬁc technologies enables the development of full-length
(i.e., regular antibody architecture) bispeciﬁc antibodies for T-
cell recruitment approaches. A frontrunner full-length bispe-
ciﬁc antibody program is being presented by Eric Smith
(Regeneron Pharmaceuticals). He will discuss the advantages of
their human full-length CD20xCD3 bispeciﬁc antibody. Next,
another full length bispeciﬁc antibody product will be discussed
by Francois Gaudet (Janssen). In vitro, ex vivo and in vivo data
of this CD123xCD3 bispeciﬁc antibody, currently in Phase 1
clinical study for acute myeloid leukemia, will be shared and
discussed. This talk will be followed by a networking refresh-
ment break.
Many of the validation and clinical studies done on CAR-T
cells involves CD19 as a target antigen. A bispeciﬁc CAR-T,
speciﬁc for CD19 and CD20, might strengthen the clinical
efﬁcacy and overcome potential loss of CD19 expression, and
so aims to combat tumor heterogeneity. Yvonne Chen (Univer-
sity of California, Los Angeles) will demonstrate the power of
such a bispeciﬁc CAR-T. Although so far this session has
focused on T-cell therapies for cancer, T cells could of course
also be used to kill infectious disease targets. Guido Ferrari
(Duke University Medical Center) will discuss exciting advan-
tages of using a bispeciﬁc T-cell recruiting antibody for killing
latently HIV-1 infected CD4C T cells. The last speaker of this
session, Mark Cobbold (Massachusetts General Hospital
Cancer Center), will present a novel approach where T cells are
engaged for tumor cell killing. The abundantly highly potent
tumor-resident immune cells against persistent viral pathogens
are being retargeted by a new technology named redirected
viral immunotherapy.
Novel engineering strategies to enhance antibody
functions
Chairman: Paul J. Carter, Senior Director and Staff Scientist,
Antibody Engineering, Genentech.
A common theme with this conference since its inception in
the 1990s has been the presentation of new antibody engineer-
ing technologies and their application to enhance the clinical
potential of antibodies. Indeed, many therapeutic antibodies –
approved or in clinical development - have been engineered to
improve existing functional properties, to provide them with
new activities or to enhance their developability characteristics.
Antibody technologies to be highlighted in this session include
antibody fusion proteins, bispeciﬁc antibodies, and engineering
to improve other antibody attributes such as protease resistance
and antiviral activity.
Jan Terje Andersen (Oslo University) will present on the
cytosolic Fc receptor, known as TRIM21, that binds to anti-
body-opsonized viral particles and can induce efﬁcient neutrali-
zation and inﬂammatory signaling. Antibody engineering has
been used to modulate the antiviral properties of antibodies to
enhance their therapeutic potential. William Strohl (Janssen
R&D) will describe antibody-fusion constructs that opsonize
and kill methicillin-resistant Staphylococcus aureus (MRSA).
Antibodies were engineered to be protease-resistant to evade
their inactivation by bacterial proteases. Dario Neri (ETH Zur-
ich) will discuss antibody-cytokine fusion proteins for the treat-
ment of cancer or chronic inﬂammation. The design,
preclinical and clinical characterization of antibody-cytokine
fusion proteins will be presented.
After the networking break, Peter Br€unker (Roche Glycart)
will present on a novel CEA-targeting T-cell bispeciﬁc antibody
for the treatment of solid tumors. This molecule is currently
under investigation in Phase 1 clinical studies. The ﬁnal
two talks of this session will focus on engineering strategies to
facilitate the efﬁcient production of bispeciﬁc IgG by coexpres-
sion of 2 different IgG molecules in a single host cell. Itai Ben-
har (Tel-Aviv University) will describe a strategy to facilitate
correct heavy and light pairing using an engineered disulﬁde
bond. A novel LC-MS-MS approach will be presented for
precise assessment of chain pairing. Nathan Higginson-Scott
(Pﬁzer) will describe CH1 and Ck mutations from rational
design and combinatorial screening that can promote the
efﬁcient assembly of correct antibody heavy and light pairs.
Parameters considered in evaluating designs include chain
pairing ﬁdelity, product homogeneity, expression levels, and
developability characteristics.
Special session of the antibody society
Moderator: Janice M. Reichert, Ph.D., Executive Director, The
Antibody Society; Editor-in-Chief, mAbs; Managing Director,
Reichert Biotechnology Consulting LLC.
The Antibody Society is a non-proﬁt association represent-
ing individuals and organizations involved in antibody research
and development. The Society engages in activities that broadly
beneﬁt members, such as education and publishing, and
encourage collaboration between companies, academia and
government organizations. This special session will provide an
update on late-stage antibody therapeutics development and
initiatives prioritized by the Society in 2016. Janice Reichert
(The Antibody Society) will recapitulate the approvals granted
for antibody therapeutics in 2016 in the United States or Euro-
pean Union, 21 and summarize the “Antibodies to watch” in
2017, i.e., mAbs in regulatory review and those with clinical
studies due for completion in 2017. She will also brieﬂy discuss
the Society’s initiative to address questions22 surrounding the
World Health Organization’s international non-proprietary
naming system.
Andrew Bradbury (Los Alamos National Laboratory) will
then review progress made during 2016 on the Society’s initia-
tive to address issues related to antibody reagent
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reproducibility. In collaboration with the Global Biological
Standards Institute, the Society organized the workshop
“Research Antibodies: Solutions for Today and Tomorrow”,
held at Asilomar in October 2016, with the goals to: 1) identify
a set of standards to validate research antibodies, including rec-
ommendations for adoption by academia, industry, funders,
and journals; 2) develop recommendations for an independent
proﬁciency certiﬁcation system or open access user ratings ser-
vice; and 3) develop recommendations, timeline, and follow-up
plan for the introduction of sequenced recombinant antibodies
as research reagents. Dr. Bradbury will discuss the outcome of
the Asilomar meeting and future plans for this initiative.
The Society supports the Adaptive Immune-Receptor Rep-
ertoire (AIRR) Community in developing recommendations
for: 1) a common repository for AIRR sequence data, 2) mini-
mal standards for publishing and depositing AIRR sequence
data, and 3) resources and guidelines for the evaluation of
molecular and statistical methods for AIRR sequence data,
which were discussed at a workshop held at the National Insti-
tutes of Health’s Fishers Lane Facility in Rockville, MD in June
2016. Jamie K. Scott (Simon Fraser University) will provide an
update on progress in these areas, and she will discuss future
plans for this initiative.
Thursday, December 15, 2016, morning
Beyond ADCC and CDC – biological impact of Fc receptor
engagement
Chairwoman: Trudi Veldman, Ph.D., Senior Director Biologics,
Abbvie
The Fc regions of antibodies contribute important biologics
functions such as antibody-dependent cell-mediated cytotoxicity
(ADCC) and complement-dependent cytotoxicity (CDC) through
interaction with activating Fcg receptors – processes that are well
known to be essential contributors to antibody efﬁcacy for cancer
indications. More recently, it has become apparent that interac-
tions with the inhibitory FcgR also play a role in presentation and
clustering of antibodies and convey full efﬁcacy of several agonistic
antibodies, such as those targeting CD40.
This session will kick off with two presentations focusing on
engagement of FcgRIIb. David Szymkowski (Xencor) will dis-
cuss engineered Fc domains with optimized afﬁnity and selec-
tivity for Fc receptors and present case studies of two
antibodies, engineered to engage the inhibitory receptor
FcgRIIb, that are currently in clinical trials for allergy, SLE and
IgG4-related disease. Yuki Iwayanagi (Chugai) employs pH-
dependent binding to FcgRIIb to enhance the cellular uptake of
monomeric and multimeric antigen/antibody complexes in
vivo, thereby accelerating soluble antigen clearance from circu-
lation without compromising antibody half-life.
Serum antibody half-life manipulation through altering the
Fc interaction with FcRn has been a main feature in therapeutic
antibody engineering. Anke Kretz-Rommel (Bird Rock Bio)
will share clinical data on gerilimzumab, an anti-IL-6 antibody
with a half-life of » 50 days in human subjects. Hans de Haard
(Argenx) will describe clinical data with ARGX-113, an anti-
body that, through speciﬁc engagement with FcRn, causes rapid
clearance of pathogenic antibodies.
Tumor necrosis factor (TNF) inhibitors (antibodies and
receptor fusion protein) have been on the market for more
than a decade and are approved for many indications in the
ﬁelds of arthritis, inﬂammatory bowel disease (IBD) and
dermatology. One would have expected that the mechanism
of action of anti-TNF would be similar in these indications
and would be well understood after this many years of
research. While inhibition of TNF with any TNF inhibitor
currently on the market results in efﬁcacy in arthritis,
mucosal healing in patients with IBD is only observed with
IgG1 anti-TNF antibodies. Felicia Bloemendaal (University
of Amsterdam) will show that FcgR signaling is required
for the response to anti-TNF in IBD and that anti-TNFs
induce regulatory macrophages in an Fc receptor dependent
manner.
In the ﬁnal talk of the session, David Humphreys (UCB)
will present an interesting concept of using carefully designed
Fc formats with controlled hexa-valency, the so called “Fc-mul-
timer”, to tailor the desired effector function while managing
potential safety concerns. Fc-multimer may have clinical poten-
tial as a recombinant protein replacement of intravenous
immunoglobulin for the treatment of auto-inﬂammatory
immune disorders.
Thursday, December 15, 2016, morning and afternoon
Antibody-drug conjugates: Preclinical and clinical sessions
Chairman: Gregory P. Adams, Ph.D., Chief Development Ofﬁ-
cer, Viventia Bio.
This year’s conference will have two back-to-back sessions
focused on the development and use of antibody-drug conju-
gates (ADCs), fusion proteins and related agents. The day will
highlight novel constructs, modeling to better understand the
distribution of these agents and preclinical/clinical ADC
development.
The morning session, “Novel ADC Constructs and ADC
Distribution” will start with a talk by Thomas Sandal
(Crescendo Biologics) describing conjugates and fusions based
upon single domain antibody fragments known as Humabod-
ies. The potential beneﬁts of these small Humabody Drug
Conjugates (HDCs) over larger ADCs include the ability to uti-
lize “plug and play” engineering to rapidly evaluate multiple
formats, their exceptionally fast tumor penetration and their
low systemic exposure. Due to their extremely potent payloads
and general lack of susceptibility to multi-drug resistance
mechanisms, immunotoxins have the potential to be game
changers in the targeted payload ﬁeld. However, they must be
de-immunized in order to be effectively used for the treatment
of cancer. Ronit Mazor (National Cancer Institute) will discuss
her work using a new approach to induce immune tolerance in
order to develop Immunotoxins with low immunogenicity.
Nick Cox (Stanford University) will describe his work develop-
ing and evaluating drug conjugates utilizing extremely stable
peptides with disulﬁde-bonded cores known as knottins. Knot-
tin peptide-drug conjugates (KDC) are readily synthesized and
have the potential for increased tumor penetration. Preclinical
results with anti-integrin KDCs and Fc-KDC fusions will be
presented.
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Two speakers will describe their work developing and vali-
dating computational models that can be used to predict the
binding and distribution of antibodies/ADCs in the tumor
environment. John Rhoden (Eli Lilly) will present a novel and
experimentally validated conceptual/mathematical model of
the interactions between antibodies (bivalent vs. bispeciﬁc) and
cell surface antigens. The model incorporates critical proper-
ties, including the structure and ﬂexibility of key components
such as the antibody, the target antigen(s) and the binding epi-
tope(s), as well as antigen density and the expression levels of
each antigen when bispeciﬁc antibodies are employed. Greg
Thurber (University of Michigan) has developed a multiscale
model of ADCs that couples systemic and organ-level distribu-
tion with tissue-level distribution. He will discuss this model
and describe its use in understanding the distribution of
Kadcyla (ado-trastuzumab emtansine; T-DM1) in HER2-pos-
itive mouse xenograft models, including the effect of drug-anti-
body ratios, the result of drug deconjugation, and the impact of
unconjugated antibody on the penetration of ADCs into the
tumor.
The afternoon session “ADCs: Preclinical and Clinical
Development” will begin with a talk by Dennis Benjamin
(Seattle Genetics) that describes the development of new-gener-
ation ADCs based upon studies of cancer antigen targets, drug
potency and mechanism, and linker stability and conditional
drug release. The physicochemical properties of conjugates,
biodistribution, and new high-potency drugs will be discussed.
Carl Uli Bialucha (Novartis) will describe how the discov-
ery, optimization and broad in vivo functional characterization
of a novel CDH6-targeting ADC was based on a multi-factorial
lead selection campaign incorporating readouts of cell binding,
internalization propensity and in vitro cytotoxicity. This was
coupled with the selection of an optimal linker/payload pair
based on deep in vivo proﬁling, including an unbiased, high-
throughput study against a panel of 31 unselected patient-
derived ovarian xenograft models. The next talk, by Alfred Zip-
pelius (Universit€aty Hospital Basel), addresses the timely com-
bination of ADC treatment and immuno-oncology. He will
describe work demonstrating that speciﬁc ADCs are particu-
larly effective in eliciting anti-tumor immunity in poorly
immunogenic, aggressive malignancies, rendering them suscep-
tible to cancer immunotherapy.
John Lambert (ImmunoGen) will describe their develop-
ment of ADCs using novel DNA-alkylator payloads that have a
wide preclinical therapeutic window, and will present an update
on their preclinical and early clinical development. Christo-
pher Thanos (Halozyme Therapeutics) will present his work
on developing and evaluating anti-EGFR ADCs that are effec-
tive against cancers with KRAS or BRAF pathway mutations,
thereby addressing a critical limitation of EGFR targeting
agents. The anti-EGFR ADC his team developed binds efﬁ-
ciently to EGFR-overexpressing tumors, but exhibits limited
binding to EGFR on healthy tissues, potentially increasing its
potential therapeutic window.
In the ﬁnal presentation of the session, Herren Wu (Medi-
mmune) will describe a novel biparatopic anti-HER2 ADC that
binds to two non-overlapping HER2 epitopes. This ADC is
capable of mediating a greater degree of payload delivery into
HER2C tumor cells, and it is effective against tumor cells that
are refractory to, or have relapsed after, Kadcyla treatment.
Preclinical efﬁcacy studies and non-human primate safety stud-
ies will be shared with the audience.
Disclosure of potential conﬂicts of interest
No potential conﬂicts of interest were disclosed.
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